CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 67 enrolled
Drug / intervention
Mirikizumab Test +2 morebiological
Likely dose
Mirikizumab single dose administered subcutaneously or intravenouslyAI-extracted
Key inclusion· 3
  • ✓BMI >18 and ≤32 kg/m²
  • ✓Medical test results acceptable for the study
  • ✓Willing to be available for the whole study and follow study procedures
Key exclusion· 4
  • ✕Currently participating or recently participated in an incompatible clinical trial or medical research
  • ✕Known allergies to compounds or drugs similar to Mirikizumab
  • ✕Previously participated or withdrawn from this study
  • ✕Health problems or medical test results that could make it unsafe to participate or interfere with results

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03053622
NCT03053622Phase 1Completed
CompareCT.gov

A Phase 1, Single-Dose Study to Assess the Relative Bioavailability, Absolute Bioavailability, and Tolerability of LY3074828 Formulations in Healthy Subjects

Eli Lilly and Company·interventional·Posted Feb 15, 2017·Updated Feb 21, 2024

In Brief

A Phase 1 clinical trial evaluating Mirikizumab Test and Mirikizumab Reference for Healthy. Completed, enrolled 67 participants across 1 site.

Detailed Summary

This study is conducted to compare how much mirikizumab, in two different formulations, is absorbed into the bloodstream and how long the body takes to get rid of it, when given as an injection under the skin or into the veins. Side effects of the injection will be collected. Each participant will be in the study for about 18 weeks, including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 15, 2017
Enrollment StartApr 24, 2017
Primary CompletionApr 3, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.4 years ago

Interventions

Mirikizumab Testbiological

Administered SC

Mirikizumab Testbiological

Administered IV

Mirikizumab Referencebiological

Administered SC